Sun Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sun Pharmaceutical (Princeton, NJ): 48 reconciled FDA prescription therapies (21.9% 2025 to 2030 cliff risk), $472.8M 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterPrinceton, NJ
Reconciled FDA Portfolio Therapies48
2025 to 2030 Patent-Cliff Revenue Exposure21.9%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$472.8M
2024 Medicare Part D Spend$240.3M
2024 Medicaid Spend$232.5M
California HCAI SB 17 Filings11 WAC filings (max 21.1% 2-yr change)